# PSMA-guided biopsy raised cancer detection in one trial

> A single-center randomized study found more prostate cancers and fewer complications with a PET-guided robotic workflow, but it did not isolate the value of PET or establish a new standard of care.

_Source: Journal of Nuclear Medicine randomized trial, checked against PubMed, ClinicalTrials.gov, Crossref, OpenAlex, and the originating Telegram post · 2026-09-11 · 7 min read · Verified against primary sources_

Canonical: https://iyu.app/e/psma-pet-robot-prostate-biopsy-trial

## The 60-second version

A single-center randomized trial found higher procedure-level cancer detection and fewer complications with a PSMA PET/CT-guided robotic biopsy workflow than with cognitive-fusion transrectal biopsy.

**Key points**

- The study randomized 217 biopsy-naive men with PI-RADS 4 or 5 MRI lesions: 112 to the PET pathway and 105 to the comparator.
- The headline detection result was 101/104 after PET-guided biopsy versus 85/105 in the comparison arm; eight PET-arm randomizations were outside the headline procedure denominator.
- Reported complications were 10.8% versus 51.4%, and median pain was 3 versus 5, but multiple parts of the biopsy workflow differed at once.
- The open-label, single-center pilot reported any prostate-cancer detection and does not establish routine PSMA PET screening or replacement of MRI.

**Verdict.** A strong signal worth multicenter confirmation, with intention-to-treat and clinically significant-cancer outcomes, before changing standard practice.

## Full explainer

A **single-center randomized trial** found more prostate cancers with a [gallium-68 PSMA-11 PET/CT-guided robotic biopsy](https://doi.org/10.2967/jnumed.126.272036) workflow than with MRI cognitive-fusion transrectal ultrasound biopsy. It also reported fewer complications and less pain. The result is promising, but it compares two complete procedures in a selected population; it does not prove that PET alone produced the advantage or that routine care should change.

> **⚑ Caveat:** The headline 97.1% rate is **101 cancers among 104 men who received PET-guided biopsy**, although 112 men were randomized to that arm. The protocol redirected PET-negative participants to the other biopsy method. Read this as a procedure-level result, not a clean 112-versus-105 intention-to-treat comparison.


### Design — Who was actually studied

The [PROBIOP trial](https://clinicaltrials.gov/study/NCT05137561) enrolled biopsy-naive men at one center in Chandigarh, India. The paper says participants were 50–90 years old, had PSA of at least 4 ng/mL and abnormal digital rectal examination findings, and all received multiparametric MRI.

Of 267 enrolled men, 217 had **PI-RADS 4 or 5 lesions** and were randomized. This was therefore not a general screening study: the analyzed population already had highly suspicious MRI findings for which targeted biopsy is ordinarily considered.

- **267** — men enrolled
- **217** — with PI-RADS 4–5 lesions randomized
- **1** — center; open-label pilot

- **PET-guided arm:** 112 randomized; 104 received PSMA PET/CT-guided robotic biopsy and formed the headline detection denominator.
- **Comparison arm:** 105 randomized to mpMRI cognitive-fusion transrectal ultrasound-guided biopsy.
- **Primary outcome:** Detection of prostate cancer; the abstract does not separately headline clinically significant cancer.
- **Rescue pathway:** PET-negative participants in arm 1 moved to cognitive-fusion biopsy; biopsy-negative participants in arm 2 received PET and PET-guided biopsy.


### Results — The signal was large, but the denominator matters

Cancer was found in **101 of 104** men who underwent PET-guided robotic biopsy, versus **85 of 105** in the cognitive-fusion arm. The reported rates were 97.1% and 81.0%, with P < 0.05. The PET-guided arm also had a higher proportion of positive tissue cores despite taking fewer cores.

- **101/104** — cancer detected after PET-guided biopsy
- **85/105** — cancer detected in the comparison arm
- **3 vs 5** — median pain score

For PI-RADS 5 lesions, the paper reports diagnostic accuracy of 100% versus 95.1%, but **P = 0.09**. That subgroup result is not statistically persuasive at the conventional 0.05 threshold and should not be presented as a proven difference.


### Safety — Fewer complications came with a different workflow

The authors reported complications in **10.8%** of the PET-guided arm and **51.4%** of the cognitive-fusion arm, with five major complications only in the latter. Median pain and procedure time were also lower in the PET-guided arm.

> **i** This was not an imaging-only comparison. PET targeting, robotic assistance, biopsy execution, number of cores, and the comparator's transrectal workflow changed together. The trial cannot assign every safety or detection difference to PSMA PET itself.


### Limits — What the trial does not establish

- **One center:** local expertise and equipment may have amplified performance; multicenter replication is needed.
- **Open-label pilot:** participants and operators knew the assigned procedure, and the registry describes the study as a pilot.
- **Selected patients:** all randomized men had PI-RADS 4 or 5 lesions; the trial does not justify PSMA PET as a general PSA screening test.
- **Outcome boundary:** the abstract emphasizes detection of any prostate cancer, not a separately reported primary endpoint for clinically significant disease.
- **Resource questions:** radiation, tracer availability, robot access, cost and comparative cost-effectiveness were not resolved by the reported detection result.
- **Incomplete reporting in the abstract:** detailed adverse-event grades, pathology distribution and full intention-to-treat estimates require the complete paper and further studies.

> A higher procedure-level detection rate is a reason for a larger trial, not by itself a new standard of care.


### Practice — What patients and clinicians should do

For people already facing biopsy after a PI-RADS 4 or 5 MRI finding, the study supports asking whether targeted-biopsy options differ in route, anesthesia, infection risk, expertise, availability and cost. It does **not** show that MRI can be skipped, that biopsy is unnecessary, or that every elevated PSA should lead to PSMA PET. Clinical decisions should remain individualized with a urologist while larger multicenter evidence develops.


## Primary sources

- [Telegram post 1475](https://t.me/CNSmydream/1475)
- [Journal of Nuclear Medicine paper (DOI)](https://doi.org/10.2967/jnumed.126.272036)
- [PubMed record (PMID 42315309)](https://pubmed.ncbi.nlm.nih.gov/42315309/)
- [ClinicalTrials.gov registration (NCT05137561)](https://clinicaltrials.gov/study/NCT05137561)
- [Crossref metadata](https://api.crossref.org/works/10.2967/jnumed.126.272036)
- [OpenAlex record](https://openalex.org/W7165146166)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._